Importantly, the efficacy of XCT790 against the p53-defective pathway is recapitulated in in vivo tumor models, showing increased anti-tumorigenic effects on p53-mutant tumors in a colon patient-derived xenograft model (Fig. 6). The gene discussed is TP53; the disease is neoplasm.